ODTX earnings date and last-quarter result: next report 2026-09-16, last quarter miss, P/E -3.45. Updated 2026-07-23.
Odyssey Therapeutics (ODTX) Research Hub
Odyssey Therapeutics (ODTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 19.3 USD (-1.53%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.45, market cap 0.55B. This hub links to the full technical, earnings and options research available for ODTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 19.3 USD (-1.53%) |
| 52-week range | 15.5 USD – 29.05 USD |
| Trend regime | Range |
| 14-day RSI | 57.8 (Bullish) |
| Trailing P/E | -3.45 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-16 |
Available research for ODTX
Covered Call on ODTX: how it works, illustrative setup around the real 19.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ODTX: how it works, illustrative setup around the real 19.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ODTX: how it works, illustrative setup around the real 19.3 USD price, max profit/loss, breakeven and when to use it. Educational.
ODTX technical analysis: range, last 19.3 USD, RSI 57.8, 52w range 15.5 USD–29.05 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ODTX in?
Odyssey Therapeutics (ODTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ODTX in an uptrend or downtrend?
As of 2026-10-26, ODTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ODTX's trailing P/E ratio?
ODTX's trailing P/E is -3.45, with a market cap of 0.55B. See the earnings research page for full valuation detail.
When does ODTX next report earnings?
ODTX is next scheduled to report earnings on 2026-09-16.